Cargando…
Neutralization titer biomarker for antibody-mediated prevention of HIV-1 acquisition
The Antibody Mediated Prevention trials showed that the broadly neutralizing antibody (bnAb) VRC01 prevented acquisition of human immunodeficiency virus-1 (HIV-1) sensitive to VRC01. Using AMP trial data, here we show that the predicted serum neutralization 80% inhibitory dilution titer (PT(80)) bio...
Ejemplares similares
-
Neutralization profiles of HIV-1 viruses from the VRC01 Antibody Mediated Prevention (AMP) trials
por: Mkhize, Nonhlanhla N., et al.
Publicado: (2023) -
Sequence and functional characterization of a public HIV-specific antibody clonotype
por: Murji, Amyn A., et al.
Publicado: (2021) -
Despite delayed kinetics, people living with HIV achieve equivalent antibody function after SARS-CoV-2 infection or vaccination
por: Motsoeneng, Boitumelo M., et al.
Publicado: (2023) -
AAV-Mediated Expression of Broadly Neutralizing and Vaccine-like Antibodies Targeting the HIV-1 Envelope V2 Region
por: van den Berg, Fiona T., et al.
Publicado: (2019) -
Combining Viral Genetics and Statistical Modeling to Improve HIV-1 Time-of-Infection Estimation towards Enhanced Vaccine Efficacy Assessment
por: Rossenkhan, Raabya, et al.
Publicado: (2019)